PAVmed (NASDAQ:PAVM) issued its earnings results on Sunday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.06), MarketWatch Earnings reports.
PAVM stock opened at $5.55 on Tuesday. The stock has a market cap of $399.07 million, a P/E ratio of -7.30 and a beta of 0.13. The stock’s fifty day simple moving average is $2.59 and its two-hundred day simple moving average is $2.08. PAVmed has a 1-year low of $1.30 and a 1-year high of $5.63.
A number of equities analysts have recently weighed in on PAVM shares. Lake Street Capital upped their target price on PAVmed from $5.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday. Ascendiant Capital Markets initiated coverage on shares of PAVmed in a research note on Thursday, November 5th. They issued a “buy” rating and a $5.00 price objective on the stock.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Featured Article: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.